[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-350446-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-350446-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","cdk46-targeted-therapy-for-gastrointestinal-cancers-from-resistance-mechanisms-to-immuno-combination-strategies-guided-by-biomarkers","CDK4/6-targeted therapy for gastrointestinal cancers - from resistance mechanisms to immuno-combination strategies guided by biomarkers","","Gastrointestinal cancers impose a high global burden, and advanced disease often lacks effective options, creating an urgent need for new targeted treatments. This review focuses on how CDK4/6 inhibitors—by arresting the G1/S cell-cycle checkpoint—reshape the tumor immune microenvironment and support combinations with immune checkpoint inhibitors. It details mechanisms underlying primary and acquired resistance, then emphasizes biomarker detection, therapeutic target assessment, and precision molecular subtyping to guide effective CDK4/6-based regimens.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/cdk46-targeted-therapy-for-gastrointestinal-cancers-from-resistance-mechanisms-to-immuno-combination-strategies-guided-by-biomarkers/350446/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/cdk46-targeted-therapy-for-gastrointestinal-cancers-from-resistance-mechanisms-to-immuno-combination-strategies-guided-by-biomarkers/350446.png","ImageObject",300,407,{"name":42,"@type":43},"McGucket","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-30","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",13,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the main therapeutic rationale for CDK4/6 inhibitors in gastrointestinal cancers?","Question",{"text":63,"@type":64},"CDK4/6 inhibitors block CDK4/6 activity, inhibit RB phosphorylation, induce G1 arrest, and thereby suppress tumor cell proliferation.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How do CDK4/6 inhibitors influence the tumor immune microenvironment (TIME)?",{"text":68,"@type":64},"They enhance tumor antigen presentation, reduce immunosuppressive regulatory T-cell activity, and promote effector T-cell infiltration, supporting synergy with immune checkpoint inhibitors.",{"name":70,"@type":61,"acceptedAnswer":71},"Why does resistance limit CDK4/6 inhibitor efficacy in digestive cancers?",{"text":72,"@type":64},"Frequent dysregulation of the CDK4/6-RB pathway and the complexity of the TIME can lead to primary and acquired drug resistance, restricting clinical effectiveness.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},350446,1790642905,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146,"preview_page_count":33,"preview_urls":147},1236954412713,"https://us-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","TYPE Review  \nPUBLISHED 04 June 2026  \nDOI 10.3389/fimmu.2026.1845921  \nOPEN ACCESS  \nEDITED BY  \nYinlong Zhang,  \nUniversity of Chinese Academy of Sciences, China  \nREVIEWED BY  \nLiang-min Fu,  \nCentral South University, China Manal Kanaan,  \nMiddle Technical University, Iraq  \n*CORRESPONDENCE  \nYingshuang Wang  \n[wangyingshuang@cdutcm.edu.cn](wangyingshuang@cdutcm.edu.cn)[ ](wangyingshuang@cdutcm.edu.cn)Jie Lan  \n [lanjielanjie@foxmail.com](lanjielanjie@foxmail.com)[ ](lanjielanjie@foxmail.com)RECEIVED 02 April 2026 REVISED 25 May 2026 ACCEPTED 25 May 2026 PUBLISHED 04 June 2026  \nCITATION  \nCui J, Zhang Y, Wu Y, Zhang G, Lan Jand Wang Y (2026) CDK4/6-targeted therapy for gastrointestinal cancers:  \nfrom resistance mechanisms to immuno-combination strategies guided by biomarkers.  \nFront. Immunol. 17:1845921 .  \ndoi: 10.3389/fimmu.2026.1845921  \nCOPYRIGHT  \n© 2026 Cui, Zhang, Wu, Zhang, Lan and Wang. This is an open-access article distributed under the terms of the  \nCreative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nCDK4/6-targeted therapy for gastrointestinal cancers:  \nfrom resistance mechanisms to immuno-combination strategies guided by biomarkers  \nJunhao Cui 1, Yanchuan Zhang 1, Yongfang Wu 1, Guangjie Zhang 2, Jie Lan 3* and Yingshuang Wang 1*  \n1Sichuan Key Laboratory of Medical Molecular Testing, College of Medical Technology, Chengdu University of Traditional Chinese Medicine, Chengdu, China, 2 Department of Clinical Laboratory, The Fifth People’s Hospital Afﬁliated to Chengdu University of Traditional Chinese Medicine,  \nChengdu, China, 3 Division of Head & Neck Tumor Multimodality Treatment, Cancer Center, Institute of Breast Health Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, China  \nGastrointestinal (GI) cancers, encompassing esophageal, gastric, colorectal, hepatocellular, and pancreatic cancers, represent a major global health burden with persistently high morbidity and mortality. Given the limited therapeutic options and poor prognoses for patients with advanced-stage disease, there is an urgent and unmet clinical need for novel targeted therapies. Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors (such as palbociclib, ribociclib, and abemaciclib) exert their effects by arresting the cell cycle at the G1/S checkpoint. Their landmark clinical success in hormone receptor-positive breast cancer has highlighted the therapeutic potential of targeting cell cycle regulation, thereby prompting extensive investigation into their application in solid tumors of the digestive system. Emerging evidence indicates that, beyond their direct antiproliferative effects, CDK4/6 inhibitors profoundly remodel the tumor immune microenvironment (TIME) . By enhancing tumor antigen presentation, diminishing the immunosuppressive activity of regulatory T cells (Tregs), and promoting effector T cell inﬁltration, these agents provide a robust mechanistic rationale for synergistic combinations with immune checkpoint inhibitors (ICIs) . However, the frequent dysregulation of the CDK4/6-RB pathway and the inherently complex TIME in digestive cancers often precipitate primary and acquired drug resistance, which restricts their clinical efﬁcacy. Consequently, elucidating the mechanisms that modulate drug sensitivity and developing biomarker-driven combination regimenshave become critical research priorities. This review systematically summarizes the mechanisms governing the sensitivity of digestive tract tumors to CDK4/6 inhibitors. From the perspective of laboratory medicine, we further emphasize the importance of biomarker detection, therapeutic target assessment, and precision molecular s","cbCaioKXn7n6fXBM","https://ap.wps.com/l/cbCaioKXn7n6fXBM","pdf",3325432,18,"English","# 1 Introduction\n## Cell-cycle dysregulation and the Cyclin D1-CDK4/6-RB axis\n# KEYWORDS","[{\"question\":\"What is the main therapeutic rationale for CDK4/6 inhibitors in gastrointestinal cancers?\",\"answer\":\"CDK4/6 inhibitors block CDK4/6 activity, inhibit RB phosphorylation, induce G1 arrest, and thereby suppress tumor cell proliferation.\"},{\"question\":\"How do CDK4/6 inhibitors influence the tumor immune microenvironment (TIME)?\",\"answer\":\"They enhance tumor antigen presentation, reduce immunosuppressive regulatory T-cell activity, and promote effector T-cell infiltration, supporting synergy with immune checkpoint inhibitors.\"},{\"question\":\"Why does resistance limit CDK4/6 inhibitor efficacy in digestive cancers?\",\"answer\":\"Frequent dysregulation of the CDK4/6-RB pathway and the complexity of the TIME can lead to primary and acquired drug resistance, restricting clinical effectiveness.\"}]","CDK4/6-targeted therapy for gastrointestinal cancers - from resistance mechanisms to immuno-combination strategies guided by biomarkers | PDF",1790089084,45,[148,152,156,160],{"page_no":22,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6e33f669f9782c8530af5cc822a2f10d.webp",983,1389,{"page_no":26,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5b57617f5fe48520f5e88223bf270eb1.webp",982,1388,{"page_no":30,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/045d4a190a8243b470e3b0269da3e1f9.webp",981,1386,{"page_no":33,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/65a6272ec5cb0a0d4579240f1994d630.webp",980,1385]